New combo attack on tough lymphoma shows promise in early trial
NCT ID NCT05583149
First seen Feb 01, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This phase 2 study tests whether combining the drug acalabrutinib with a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) can help people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 28 adults will receive the combination. The main goal is to see how many patients achieve a complete response (no signs of cancer).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib (Calquence) and lisocabtagene maraleucel (Breyanzi, a CAR T-cell therapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with aggressive B-cell lymphoma that has not responded to standard therapies.
What could go wrong
This is a small, early-phase (phase 2) study with only 28 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.